Literature DB >> 7803760

The Raf-1 serine/threonine protein kinase.

N S Magnuson1, T Beck, H Vahidi, H Hahn, U Smola, U R Rapp.   

Abstract

Raf-1 belongs to a family of serine/threonine protein kinases which are highly conserved through evolution in multicellular organisms. Raf-1 kinase has gained much attention due to its function as a critical shuttle enzyme that connects stimulation of growth factor receptors and protein kinase C at the cell membrane to changes in the expression of genes involved in the control of cell growth, differentiation and survival. Regulation of Raf-1 activity is complex and involves Ras, as well as several serine/threonine and tyrosine kinases. Through a series of phosphorylation events, extracellular signals are connected through the Raf-1/MAP kinase pathway to activity-regulation of several oncogene-class transcription factors via phosphorylation of specific serine residues. Under ordinary circumstances, the cascade involving Raf-1 eventually leads to changes in gene expression and protein synthesis. Upon constitutive activation of Raf-1 kinase, as a result of genetic changes, a variety of cell types acquire a transformed phenotype.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7803760

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  11 in total

1.  c-Raf regulates cell survival and retinal ganglion cell morphogenesis during neurogenesis.

Authors:  B Pimentel; C Sanz; I Varela-Nieto; U R Rapp; F De Pablo; E J de La Rosa
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation.

Authors:  C S Mason; C J Springer; R G Cooper; G Superti-Furga; C J Marshall; R Marais
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

Review 3.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

4.  Lipopolysaccharide and Raf-1 kinase regulate secretory interleukin-1 receptor antagonist gene expression by mutually antagonistic mechanisms.

Authors:  C J Guthridge; D Eidlen; W P Arend; A Gutierrez-Hartmann; M F Smith
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

5.  Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.

Authors:  B H Zhang; K L Guan
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

6.  Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway.

Authors:  T W Schulte; M V Blagosklonny; L Romanova; J F Mushinski; B P Monia; J F Johnston; P Nguyen; J Trepel; L M Neckers
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

7.  The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18.

Authors:  B Le Douarin; C Zechel; J M Garnier; Y Lutz; L Tora; P Pierrat; D Heery; H Gronemeyer; P Chambon; R Losson
Journal:  EMBO J       Date:  1995-05-01       Impact factor: 11.598

8.  Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression.

Authors:  J Rak; Y Mitsuhashi; V Erdos; S N Huang; J Filmus; R S Kerbel
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

9.  Abnormal pattern of post-gamma-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome.

Authors:  R Mirzayans; R A Aubin; W Bosnich; W A Blattner; M C Paterson
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

Review 10.  Signaling through Raf-1 in the neovasculature and target validation by nanoparticles.

Authors:  Kishore K Wary
Journal:  Mol Cancer       Date:  2003-07-30       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.